MediClin has resolved upon a capital increase by utilization of authorized capital at the ratio of 2:1 at a subscription price per share of € 2.50

Ad hoc Announcement Pursuant to § 15 WpHG (German Securities Trading Act)

Frankfurt am Main, November 21, 2008 – The management board of MEDICLIN Aktiengesellschaft, with the consent of the supervisory board, resolved today to increase the share capital via authorized capital from € 31,500,000.00 by € 15,750,000.00 to € 47,250,000.00 by issuing 15,750,000 new ordinary bearer shares with no par value (no par value shares), each share with a notional par value of € 1.00 and full dividend rights as of January 1, 2008, against cash contribution. ERGO Versicherungsgruppe Aktiengesellschaft and DKV Deutsche Krankenversicherung AG have obligated themselves to the MediClin Aktiengesellschaft to directly subscribe for the new shares underlying their subscription rights. The Landesbank Baden-Württemberg will subscribe for the remaining new shares with the obligation to offer these new shares for sale to shareholders by way of an indirect subscription right.

The new shares will be offered to the company's shareholders for subscription at the ratio of 2:1, i. e., 2 subscription rights will entitle the holder to subscribe for 1 new share. The subscription price per share will be € 2.50.

New shares that are not subscribed for in the rights offering will be offered through private placements to qualified investors outside of the United States on the basis of Regulation S under the U. S. Securities Act of 1933, as amended, as well as outside of Canada, Japan and Australia, at the subscription price.

ERGO Versicherungsgruppe Aktiengesellschaft has obligated itself to purchase at the subscription price those shares not placed through the private placements.

Important Information

This publication constitutes neither an offer to sell nor a solicitation of an offer to buy any securities. An offer will be made solely by means, and on the basis, of a prospectus to be published prior to any offering of securities of MEDICLIN Aktiengesellschaft, which will be available free of charge at MEDICLIN Aktiengesellschaft, Okenstr. 27, 77652 Offenburg, and at Landesbank Baden-Württemberg, Hauptbahnhof 2, 70173 Stuttgart. This publication and the information contained herein are not for distribution in or into the United States of America and must not be distributed to publications with a general circulation in the United States. The securities of MediClin Aktiengesellschaft have not been registered under the U. S. Securities Act of 1933, as amended, (“Securities Act”) and may not be offered, sold or delivered within the United States absent registration or an exemption from the registration requirements of the Securities Act. There will be no public offering of securities in the United States. This publication is directed only at persons (I) who are outside the United Kingdom or (II) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the “Order”) or (III) who fall within Article 49(2)(A) to (D) (“High Net Worth Companies, Unincorporated Associations etc.”) of the Order (all such persons being together referred to as “relevant persons”). Any person who is not a relevant person must not act or rely on this publication or any of its contents. Any investment or investment activity to which this publication relates is available only to relevant persons and will be engaged in only with relevant persons.

About MediClin AG (Ticker: MED; WKN: 659 510)

MediClin AG is a nation-wide clinic operator and large provider of services in the area of Psycho- and Neurosciences as well as Orthopaedic. With 33 clinics and eight nursing care facilities and three Medizinische Versorgungszentren (medical care units) in eleven federal states MediClin has a total capacity of approximately 7,900 beds. MediClin’s facilities include acute care clinics, i.e., general hospitals, special treatment facilities, specialised hospitals and clinics for post-acute treatment and medical rehabilitation. MediClin has approximately 7,800 employees.